JOHNSON & JOHNSON (1JNJ.MI) Stock Price & Overview
BIT:1JNJ • US4781601046
The current stock price of 1JNJ.MI is 212.85 EUR. Today 1JNJ.MI is up by 3.3%. In the past month the price increased by 15.38%. In the past year, price increased by 45.73%.
1JNJ.MI Key Statistics
- Market Cap
- 512.82B
- P/E
- 23.26
- Fwd P/E
- 21.57
- EPS (TTM)
- 9.15
- Dividend Yield
- 2.14%
1JNJ.MI Stock Performance
1JNJ.MI Stock Chart
1JNJ.MI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to 1JNJ.MI. When comparing the yearly performance of all stocks, 1JNJ.MI is one of the better performing stocks in the market, outperforming 88.1% of all stocks.
1JNJ.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1JNJ.MI. While 1JNJ.MI has a great profitability rating, there are some minor concerns on its financial health.
1JNJ.MI Earnings
On January 21, 2026 1JNJ.MI reported an EPS of 2.46 and a revenue of 24.56B. The company missed EPS expectations (-0.13% surprise) and beat revenue expectations (0.67% surprise).
1JNJ.MI Forecast & Estimates
32 analysts have analysed 1JNJ.MI and the average price target is 197.11 EUR. This implies a price decrease of -7.39% is expected in the next year compared to the current price of 212.85.
For the next year, analysts expect an EPS growth of 7.88% and a revenue growth 7.21% for 1JNJ.MI
1JNJ.MI Groups
Sector & Classification
1JNJ.MI Financial Highlights
Over the last trailing twelve months 1JNJ.MI reported a non-GAAP Earnings per Share(EPS) of 9.15. The EPS increased by 8.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.46% | ||
| ROA | 13.46% | ||
| ROE | 32.87% | ||
| Debt/Equity | 0.56 |
1JNJ.MI Ownership
1JNJ.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.04 | 187.74B | ||
| SNW | SANOFI | 9.04 | 187.692B | ||
| 1SAN | SANOFI | 9.02 | 187.378B | ||
| UNC | UCB SA | 24.38 | 51.176B | ||
| UCB | UCB SA | 24.41 | 50.164B | ||
| MRK | MERCK KGAA | 12.81 | 49.217B | ||
| BAYN | BAYER AG-REG | 7.45 | 37.111B | ||
| 1BAYN | BAYER AG-REG | 7.65 | 36.973B | ||
| IPN | IPSEN | 14.11 | 13.795B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.15 | 9.95B | ||
| VIRP | VIRBAC SA | 16.3 | 2.907B | ||
| DMP | DERMAPHARM HOLDING SE | 15.26 | 2.062B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1JNJ.MI
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 138100
Phone: 17325242455
JOHNSON & JOHNSON / 1JNJ.MI FAQ
What does 1JNJ do?
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
What is the stock price of JOHNSON & JOHNSON today?
The current stock price of 1JNJ.MI is 212.85 EUR. The price increased by 3.3% in the last trading session.
What is the dividend status of JOHNSON & JOHNSON?
JOHNSON & JOHNSON (1JNJ.MI) has a dividend yield of 2.14%. The yearly dividend amount is currently 4.36.
What is the ChartMill rating of JOHNSON & JOHNSON stock?
1JNJ.MI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of JOHNSON & JOHNSON (1JNJ.MI)?
The PE ratio for JOHNSON & JOHNSON (1JNJ.MI) is 23.26. This is based on the reported non-GAAP earnings per share of 9.15 and the current share price of 212.85 EUR.
How many employees does JOHNSON & JOHNSON have?
JOHNSON & JOHNSON (1JNJ.MI) currently has 138100 employees.
Who owns JOHNSON & JOHNSON?
You can find the ownership structure of JOHNSON & JOHNSON (1JNJ.MI) on the Ownership tab.